专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2013144273A1 BASAL INSULIN THERAPY 审中-公开
标题翻译：基本胰岛素治疗
公开(公告)号：WO2013144273A1
公开(公告)日：2013-10-03
申请号：PCT/EP2013/056661
申请日：2013-03-28
申请人： SANOFI
发明人： JOHNSTON, Peter , GERSTEIN, Hertzel
IPC分类号： A61K38/28 , A61P3/10 , A61P9/10
CPC分类号： A61K38/28 , A61J1/14
摘要： The present invention relates to the use of use of a long-acting insulin, in particular insulin glargine, in a method of reducing the risk of progression to type 2 diabetes in a patient, a method of reducing the risk of a new angina in a patient and a method of reducing the risk of a microvascular event in a patient comprising administering to said patient in need thereof a therapeutically effective dosage of a long acting insulin, wherein said therapeutically effective dosage of said long acting insulin reduces said risks.
摘要翻译：本发明涉及使用长效胰岛素，特别是甘精胰岛素在降低患者中进展为2型糖尿病的风险的方法中的用途，降低新型心绞痛风险的方法患者和降低患者微血管事件风险的方法，包括向有需要的所述患者施用治疗有效剂量的长效胰岛素，其中所述长效胰岛素的治疗有效剂量降低所述风险。

2. 发明申请

WO2013072328A1 USE OF TELAPREVIR AND RELATED COMPOUNDS IN ATHEROSCLEROSIS, HEART FAILURE, RENAL DISEASES, LIVER DISEASES OR INFLAMMATORY DISEASES 审中-公开
标题翻译：特拉维夫及相关化合物在心包炎，心脏衰竭，肾病，肝脏疾病或炎症疾病中的应用
公开(公告)号：WO2013072328A1
公开(公告)日：2013-05-23
申请号：PCT/EP2012/072539
申请日：2012-11-14
申请人： SANOFI
发明人： RUF, Sven , SADOWSKI, Thorsten , WIRTH, Klaus , SCHREUDER, Herman , BUNING, Christian , FRÜHBEIS, Bärbel , TILLNER, Joachim , CZICH, Andreas , PÄHLER, Tobias
IPC分类号： A61K31/497 , A61P7/02 , A61P7/10 , A61P9/10 , A61P25/28 , A61P11/00 , A61P11/06 , A61P13/12
CPC分类号： A61K31/497
摘要： Use of Telaprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases The present invention relates to a compound of the formula I for use in the treatment of atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases.
摘要翻译：特拉匹韦及其相关化合物在动脉粥样硬化，心力衰竭，肾脏疾病，肝脏疾病或炎性疾病中的用途本发明涉及用于治疗动脉粥样硬化，心力衰竭，肾脏疾病，肝脏疾病或炎性疾病的式I化合物。

3. 发明申请

WO2015185672A2 NEW MARKERS FOR THE ASSESSMENT OF AN INCREASED RISK FOR MORTALITY 审中-公开
标题翻译：评估增加风险风险的新标志
公开(公告)号：WO2015185672A2
公开(公告)日：2015-12-10
申请号：PCT/EP2015/062460
申请日：2015-06-03
申请人： SANOFI
发明人： HESS, Sybille , GERSTEIN, Hertzel , PARE, Guillaume , MCQUEEN, Matthew
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N33/68 , G01N2570/00 , G01N2800/325
摘要： The present invention relates to methods for assessing an increased risk for mortality comprising the determination of biochemical markers. It also relates to the use of the biochemical markers or marker panels for the assessment of an increased risk for mortality and to kits for performing the methods of the invention as well as to the therapeutic use of insulin analogues for reducing morality.
摘要翻译：本发明涉及用于评估增加的死亡风险的方法，包括测定生物化学标记物。它还涉及生物化学标记物或标记物组用于评估增加的死亡风险的用途，以及用于实施本发明方法的试剂盒以及用于减少道德的胰岛素类似物的治疗用途。

4. 发明申请

WO2013072327A1 USE OF BOCEPREVIR AND RELATED COMPOUNDS IN ATHEROSCLEROSIS, HEART FAILURE, RENAL DISEASES, LIVER DISEASES OR INFLAMMATORY DISEASES 审中-公开
标题翻译： BOCEPREVIR及相关化合物在ATHEROSCLEROSIS，心脏衰竭，肾脏疾病，肝脏疾病或炎症疾病中的应用
公开(公告)号：WO2013072327A1
公开(公告)日：2013-05-23
申请号：PCT/EP2012/072538
申请日：2012-11-14
申请人： SANOFI
发明人： RUF, Sven , SADOWSKI, Thorsten , WIRTH, Klaus , SCHREUDER, Herman , BUNING, Christian , FRÜHBEIS, Bärbel , TILLNER, Joachim , CZICH, Andreas , PÄHLER, Tobias
IPC分类号： A61K31/403 , A61P9/00
CPC分类号： A61K31/403
摘要： Use of Boceprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases. The present invention relates to a compound of the formula I for use in the treatment of atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases.
摘要翻译：使用波普瑞韦和相关化合物在动脉粥样硬化，心力衰竭，肾脏疾病，肝脏疾病或炎性疾病中的应用。本发明涉及用于治疗动脉粥样硬化，心力衰竭，肾脏疾病，肝脏疾病或炎性疾病的式I化合物。

5. 发明申请

WO2014161835A1 MODIFIED BLOOD GLUCOSE REGULATING PROTEINS WITH ALTERED PHARMACOLOGICAL ACTIVITY PROFILE AND PREPARATION THEREOF 审中-公开
标题翻译：改良血液葡萄糖调节蛋白与改变的药理活性分布及其制备
公开(公告)号：WO2014161835A1
公开(公告)日：2014-10-09
申请号：PCT/EP2014/056496
申请日：2014-04-01
申请人： SANOFI
发明人： WENDRICH, Thomas , WERNER, Ulrich , TENNAGELS, Norbert , KORN, Marcus Hermann , SEIPKE, Gerhard , STILLGER, Thomas , HABERMANN, Paul , SCHMIDT, Ronald
IPC分类号： C07K14/62 , A61K38/28
CPC分类号： C07K14/622 , A61K38/00
摘要： The present invention relates to modified insulin analogs with improved activity profiles, methods of preparing these molecules, pharmaceutical formulations thereof, as well as their use in therapy. Further the invention relates to methods for inhibiting protease degradation in serum and/or increasing serum stability of said modified insulin analogs, preferably by attaching one or more D-amino acids, in particular D-Arg, to the C-terminus of said insulin analogs.
摘要翻译：本发明涉及改进的活性谱的胰岛素类似物，制备这些分子的方法，其药物制剂以及它们在治疗中的用途。此外，本发明还涉及用于抑制所述修饰的胰岛素类似物的蛋白酶降解和/或增加血清稳定性的方法，优选通过将一个或多个D-氨基酸，特别是D-Arg附着到所述胰岛素类似物的C末端。

6. 发明申请

WO2011144673A2 LONG - ACTING FORMULATIONS OF INSULINS 审中-公开
标题翻译：长效胰岛素制剂
公开(公告)号：WO2011144673A2
公开(公告)日：2011-11-24
申请号：PCT/EP2011/058079
申请日：2011-05-18
申请人： SANOFI , BECKER, Reinhard , FRICK, Annke , BODERKE, Peter , FUERST, Christiane , MUELLER, Werner , TERTSCH, Katrin , WERNER, Ulrich , LOOS, Petra , SCHOETTLE, Isabell
发明人： BECKER, Reinhard , FRICK, Annke , BODERKE, Peter , FUERST, Christiane , MUELLER, Werner , TERTSCH, Katrin , WERNER, Ulrich , LOOS, Petra , SCHOETTLE, Isabell
IPC分类号： A61K38/28 , A61K9/08 , A61P5/50 , A61P3/10 , A61K9/00 , A61K38/00 , A61K31/00
CPC分类号： A61K38/28 , A61K9/0019 , A61K9/08 , A61K38/2278 , A61K38/26 , A61K47/02 , A61K47/10 , A61K47/26
摘要： The application relates to an aqueous pharmaceutical formulation comprising 200 – 1000 U/mL [equimolar to 200 –1000 IU human insulin] of insulin glargine, with the proviso that the concentration of said formulation is not 684 U/mL of insulin glargine, and its use.
摘要翻译：本申请涉及包含200-1000U / mL [等摩尔至200-1000IU人胰岛素]甘精胰岛素的水性药物制剂，条件是所述制剂的浓度不是684U / mL甘精胰岛素，其它使用。

7. 发明申请

WO2011092187A1 OXYGEN-SUBSTITUTED 3-HETEROAROYLAMINO-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS 审中-公开
标题翻译：氧自由基取代的3-异丁酰氨基酸衍生物及其作为药物的用途
公开(公告)号：WO2011092187A1
公开(公告)日：2011-08-04
申请号：PCT/EP2011/051038
申请日：2011-01-26
申请人： SANOFI , RUF, Sven , PERNERSTORFER, Josef , SADOWSKI, Thorsten , HORSTICK, Georg , SCHREUDER, Herman , BUNING, Christian , OLPP, Thomas , SCHEIPER, Bodo , WIRTH, Klaus
发明人： RUF, Sven , PERNERSTORFER, Josef , SADOWSKI, Thorsten , HORSTICK, Georg , SCHREUDER, Herman , BUNING, Christian , OLPP, Thomas , SCHEIPER, Bodo , WIRTH, Klaus
IPC分类号： C07D231/20 , C07D231/22 , C07D401/04 , C07D401/12 , C07D403/12 , C07D405/12 , C07D413/12 , C07D417/12 , A61K31/415 , A61P9/00 , A61P11/00 , A61P37/00 , A61P25/28 , A61P29/00 , A61P13/12
CPC分类号： C07C229/36 , C07D231/20 , C07D231/22 , C07D401/04 , C07D401/12 , C07D403/12 , C07D405/12 , C07D413/12 , C07D417/12
摘要： The present invention relates to compounds of the formula I, wherein A, D, E, G, R 10 , R 30 , R 40 , R 50 and R 60 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.
摘要翻译：本发明涉及式I化合物，其中A，D，E，G，R 10，R 30，R 40，R 50和R 60具有权利要求中所示的含义，它们是有价值的药物活性化合物。它们是蛋白酶组织蛋白酶A的抑制剂，例如可用于治疗动脉粥样硬化，心力衰竭，肾脏疾病，肝脏疾病或炎性疾病等疾病。本发明还涉及制备式I化合物的方法，其用途和包含它们的药物组合物。

8. 发明申请

WO2015059302A1 STABLE FORMULATION OF INSULIN GLULISINE 审中-公开
标题翻译：胰岛素的稳定配方
公开(公告)号：WO2015059302A1
公开(公告)日：2015-04-30
申请号：PCT/EP2014/072915
申请日：2014-10-24
申请人： SANOFI
发明人： LOOS, Petra , GEHRMANN, Thomas , BERCHTOLD, Harald , WERNER, Ulrich , GANZ, Matthias
IPC分类号： A61K38/28 , A61K47/00 , A61K47/10 , A61K9/08 , A61P3/10
CPC分类号： A61K47/20 , A61K9/0019 , A61K31/198 , A61K38/28 , A61K47/18
摘要： An aqueous pharmaceutical formulation comprising 200 –1000 U/mL of insulin glulisine.
摘要翻译：包含200-1000U / mL谷维素胰岛素的水性药物制剂。

9. 发明申请

WO2014037394A1 FLUORESCENCE-LABELLED FATTY ACIDS AND USES THEREOF 审中-公开
标题翻译：荧光标记的脂肪酸及其用途
公开(公告)号：WO2014037394A1
公开(公告)日：2014-03-13
申请号：PCT/EP2013/068275
申请日：2013-09-04
申请人： SANOFI
发明人： PETRY, Stefan , NAZARÉ, Marc , SCHMIDT, Thorsten , MATTER, Hans
IPC分类号： G01N33/58 , G01N33/92
CPC分类号： G01N33/582 , G01N33/92 , G01N2405/00 , G01N2500/00
摘要： The present invention relates to a composition comprising (i) a fluorescent-labelled fatty acid and (ii) a fatty acid binding compound, wherein (a) the fatty acid component of the fluorescent- labelled fatty acid binds the fatty acid binding compound and (b) the fluorescent component of the fluorescent-labelled fatty acid and the fatty acid binding compound interact to elicit FRET (Förster resonance energy transfer) effects. Moreover, the invention is directed to a method for identifying and/or characterizing a compound of interest by contacting a fluorescent-labelled fatty acid with a fatty acid binding compound under conditions that allow for binding and for FRET (Förster resonance energy transfer) effects, and then contacting the fluorescent-labelled fatty acid bound to the fatty acid binding compound with a compound of interest and determining the change in fluorescence. In addition, the invention pertains to corresponding kits of parts and uses of the compositions and methods.
摘要翻译：本发明涉及包含（i）荧光标记的脂肪酸和（ii）脂肪酸结合化合物的组合物，其中（a）荧光标记的脂肪酸的脂肪酸组分结合脂肪酸结合化合物和（ b）荧光标记的脂肪酸和脂肪酸结合化合物的荧光组分相互作用以引发FRET（Förster共振能量转移）效应。此外，本发明涉及通过在允许结合和FRET（Förster共振能量转移）效应的条件下使荧光标记的脂肪酸与脂肪酸结合化合物接触来鉴定和/或表征目的化合物的方法，然后将与脂肪酸结合化合物结合的荧光标记的脂肪酸与感兴趣的化合物接触，并确定荧光的变化。此外，本发明涉及组合物和方法的相应的部件和用途的试剂盒。

10. 发明申请

WO2012101199A1 AMINO-SUBSTITUTED 3-HETEROAROYLAMINO-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS 审中-公开
标题翻译：氨基取代的3-杂环氨基甲酸衍生物及其作为药物的用途
公开(公告)号：WO2012101199A1
公开(公告)日：2012-08-02
申请号：PCT/EP2012/051191
申请日：2012-01-26
申请人： SANOFI , RUF, Sven , SADOWSKI, Thorsten , HORSTICK, Georg , SCHREUDER, Herman , BUNING, Christian , OLPP, Thomas , WIRTH, Klaus
发明人： RUF, Sven , SADOWSKI, Thorsten , HORSTICK, Georg , SCHREUDER, Herman , BUNING, Christian , OLPP, Thomas , WIRTH, Klaus
IPC分类号： C07D231/14 , C07D275/03
CPC分类号： C07D231/38 , C07D275/02 , C07D401/04 , C07D401/12 , C07D403/04 , C07D403/06 , C07D405/12 , C07D417/04 , C07D487/04
摘要： Amino-substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals The present invention relates to compounds of the formula (I), wherein A, D, E, G, R 10 R 11 , R 30 R 40 R 50 and R 60 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.
摘要翻译：氨基取代的3-杂芳酰氨基 - 丙酸衍生物及其作为药物的用途本发明涉及式（I）化合物，其中A，D，E，G，R 10 R 11，R 30 R 40 R 50和R 60具有这些权利要求是有价值的药物活性化合物。它们是蛋白酶组织蛋白酶A的抑制剂，例如可用于治疗动脉粥样硬化，心力衰竭，肾脏疾病，肝脏疾病或炎性疾病等疾病。本发明还涉及制备式I化合物的方法，其用途和包含它们的药物组合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式